Literature DB >> 15476945

Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor.

Takanobu Yoshimoto1, Mika Matsushita, Yukio Hirata.   

Abstract

Urotensin II (UII), originally isolated from goby urophysis, has been shown to be an endogenous ligand for an orphan G-protein-coupled receptor, GPR14. Recent development of PCR quantitative method revealed that UII and UT receptor (GPR14) were expressed in a broad range of tissues and organs, including cardiovascular and renal system, and assumed to function as an autocrine/paracrine factor. UII is a potent vasoconstrictor peptide, whose potency is greater than any other vasoconstrictors thus far known. However, its physiological roles have been found to extend far beyond the regulation of vascular tone. In this review, we focused on the mitogenic action of UII and discuss its underlying cellular mechanisms and potential physiological/pathophysiological role in various human diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476945     DOI: 10.1016/j.peptides.2004.03.028

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  9 in total

Review 1.  Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides.

Authors:  R L Juliano; K Carver; C Cao; X Ming
Journal:  J Drug Target       Date:  2012-11-19       Impact factor: 5.121

2.  Urotensin II promotes vagal-mediated bradycardia by activating cardiac-projecting parasympathetic neurons of nucleus ambiguus.

Authors:  Gabriela Cristina Brailoiu; Elena Deliu; Joseph E Rabinowitz; Douglas G Tilley; Walter J Koch; Eugen Brailoiu
Journal:  J Neurochem       Date:  2014-03-06       Impact factor: 5.372

3.  Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells.

Authors:  Myriam Iglewski; Stephen R Grant
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

4.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

5.  Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.

Authors:  David Chatenet; Thi-Tuyet M Nguyen; Myriam Létourneau; Alain Fournier
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-02       Impact factor: 5.555

6.  Urotensin II Exerts Pressor Effects By Stimulating Renin And Aldosterone Synthase Gene Expression.

Authors:  Brasilina Caroccia; Mirko Menegolo; Teresa M Seccia; Lucia Petrelli; Michele Antonello; Alice Limena; Andrea Porzionato; Raffaele De Caro; Marko Poglitsch; Gian Paolo Rossi
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

7.  A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands.

Authors:  Roberta d'Emmanuele di Villa Bianca; Emma Mitidieri; Erminia Donnarumma; Ferdinando Fusco; Nicola Longo; Giuseppe De Rosa; Ettore Novellino; Paolo Grieco; Vincenzo Mirone; Giuseppe Cirino; Raffaella Sorrentino
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

8.  Urotensin-II-Mediated Reactive Oxygen Species Generation via NADPH Oxidase Pathway Contributes to Hepatic Oval Cell Proliferation.

Authors:  XiaoTong Yu; PengYan Wang; ZhengMing Shi; Kun Dong; Ping Feng; HongXia Wang; XueJiang Wang
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

9.  Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.

Authors:  Alexander A Goldberg; Kwang-Bo Joung; Asma Mansuri; Yujin Kang; Raquel Echavarria; Ljiljana Nikolajev; Yang Sun; Jane J Yu; Stephane A Laporte; Adel Schwertani; Arnold S Kristof
Journal:  Oncotarget       Date:  2016-09-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.